The best prognosis among the AML subtypes is acute promyelocytic leukemia (APL), which harbors the t(15;17) translocation, generating the promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARA) fusion gene, and is curable with arsenic trioxide and all-trans retinoic acid (ATRA) treatment. The gene discussed is RARA; the disease is acute promyelocytic leukemia.